David Sterman
Recommend this article

If you're a subscriber of my $100,000 Real-Money Portfolio, then you know I've been focusing on stocks that have the potential for serious multi-year gains. By definition, this means stocks that are out of favor right now. And in the face of a tough stock market this spring, many have them have stayed out of favor. 

The portfolio is off roughly 7%, but I'm undeterred because I know I own a basket of compelling long-term opportunities and expect my patience to be rewarded -- handsomely.

The key for these stocks is to start delivering on the thesis I've laid out for them. As an example, I was early to the game with my pick of battery maker Exide Technologies (Nasdaq: XIDE), as the company went on to offer another dismal quarter after I bought it. Yet Exide has begun to turn the corner, with shares beginning the month trading at just $2.30, but since rallying 35% to above $3. I'm still underwater with this pick, but I expect the company's turnaround efforts to slowly being recognized by more investors, eventually getting this stock back above $5, where it stood last summer.

The FDA validates this biotech stock
Another pick in portfolio is showing signs of life as well. Shares of Ligand Pharmaceuticals (Nasdaq: LGND) are up more than 20% this week on word that the Food & Drug Administration (FDA) is likely to approve the drug carfilzomib when it votes on July 27. This is a blood cancer drug being developed by Onyx Pharmaceuticals. (Nasdaq: ONXX), which traded up a hefty 40% on the news.

Why is this good news for Ligand? 

Recommend this article

David Sterman

David Sterman has worked as an investment analyst for nearly two decades. He is currently an analyst for StreetAuthority.com
TOWNHALL FINANCE DAILY

Get the best of Townhall Finance Daily delivered straight to your inbox

Follow Townhall Finance!